Tsyabri Efficacy Rate
Posted: Wed Dec 26, 2012 3:02 pm
Does anyone know the efficacy rate of Tysabri? I tried to find it on pubmed, but I don't really know where to look in the endless reports.
Welcome to This is MS, the leading forum for Multiple Sclerosis research and support. Join our friendly community of patients, caregivers, and researchers celebrating over 20 years of delivering hope through knowledge.
https://www.thisisms.com/forum/
Read info on this link and see if you can make any sense of the numbersdaydreamer11 wrote:Does anyone know the efficacy rate of Tysabri? I tried to find it on pubmed, but I don't really know where to look in the endless reports.
Harry, not speaking to Tysabri explicitly, I have heard this statement many times (probably yourself)_ I am a bit lazy, but have they found that generally speaking, playing the "odds", the greater the number of lesions, the greater the disability? Or is it completely random when plotted on a graph? Is it at all common for people to increase in lesion load while reducing in disability? or vice versa?HarryZ wrote:They also said that the number of brain lesions was reduced significantly although lesions are known to come and go without medications and they do not correlate with MS symptoms.
Cure,CureOrBust wrote:Harry, not speaking to Tysabri explicitly, I have heard this statement many times (probably yourself)_ I am a bit lazy, but have they found that generally speaking, playing the "odds", the greater the number of lesions, the greater the disability? Or is it completely random when plotted on a graph? Is it at all common for people to increase in lesion load while reducing in disability? or vice versa?HarryZ wrote:They also said that the number of brain lesions was reduced significantly although lesions are known to come and go without medications and they do not correlate with MS symptoms.
Statisical outcomes in trials can be manipulated to "prove" a point. That's how Copaxone eventually got approved after first being rejected by the FDA for statistical insignificance. In reference to your previous question on lesions, the companies always show that there are fewer lesions for those who take the drug vs those who don't. But while being a nice stat, it doesn't translate into the drug having a good efficacy.CureOrBust wrote:even if lesions and symptoms may come and go on the individual, I think they would rely on the statistical outcomes.